News und Analysen
Newron to present at the 31st European Congress of Psychiatry
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Convatec Group PLC: Director/PDMR Shareholding
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and
Transgene: 2022 Full-year Results and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
EQS-News: Abivax adjusts its 2023 Financial Communication Calendar
Humana Healthy Horizons Invests More Than $1 Million to Help Louisianans Overcome Health Challenges
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced today that it has contributed more than $1 million to non-profit
Simulations Plus to Present at Sidoti March Small-Cap Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Sensorion Reports Full-Year 2022 Financial Results and Business Update
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today its full-year 2022
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Valbiotis veröffentlicht seine Jahresergebnisse 2022 und gibt ein Update zu seiner strategischen Roadmap
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderungswürdig (Paris: ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Waters Corporation Listed as No. 5 on Barron's 100 Most Sustainable Companies 2023 List
Waters Corporation’s (NYSE:WAT) companywide commitment to “leaving the world better than we found it” has earned it the number five ranking on the Barron’s 2023 100 Most Sustainable Companies U.S
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it entered into a
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
Regulatory News:
POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be presenting eight posters